Abstract
The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 313-315 |
| Number of pages | 3 |
| Journal | Anticancer Research |
| Volume | 12 |
| Issue number | 2 |
| State | Published - 1992 |
| Externally published | Yes |
Fingerprint
Keywords
- Antitumor activity
- Interleukin-3
- Solid tumors
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors. / Sasaki, H.; Schmitt, D. A.; Hayashi, Y.; Pollard, Richard B; Suzuki, F.
In: Anticancer Research, Vol. 12, No. 2, 1992, p. 313-315.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors
AU - Sasaki, H.
AU - Schmitt, D. A.
AU - Hayashi, Y.
AU - Pollard, Richard B
AU - Suzuki, F.
PY - 1992
Y1 - 1992
N2 - The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.
AB - The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.
KW - Antitumor activity
KW - Interleukin-3
KW - Solid tumors
UR - http://www.scopus.com/inward/record.url?scp=0026604227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026604227&partnerID=8YFLogxK
M3 - Article
VL - 12
SP - 313
EP - 315
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2
ER -